Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) shares gapped up before the market opened on Monday. The stock had previously closed at $21.58, but opened at $23.3499. Chugai Pharmaceutical shares last traded at $22.6905, with a volume of 20,992 shares changing hands.
Wall Street Analyst Weigh In
Several analysts have weighed in on the company. Nomura raised Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.
Read Our Latest Stock Analysis on CHGCY
Chugai Pharmaceutical Stock Performance
The firm has a market capitalization of $75.11 billion, a price-to-earnings ratio of 23.77 and a beta of 0.60. The business’s 50-day moving average is $20.73 and its two-hundred day moving average is $24.41.
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.27 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 35.63% and a return on equity of 24.91%. The firm had revenue of $2.54 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 1.00 EPS for the current year.
About Chugai Pharmaceutical
Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products.
The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.
Chugai serves patients and healthcare providers in Japan and works with Roche to develop and commercialize medicines internationally.
See Also
- Five stocks we like better than Chugai Pharmaceutical
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
